Design Highlights
- The program is available only to Medicare Part D beneficiaries with a BMI of 30 or higher, or 35 and above.
- Prior authorization from the prescriber is required to access the program and confirm eligibility criteria.
- Covered GLP-1 products include Foundayo, Wegovy, and Zepbound, limited to obesity-related uses only.
- A $50 copay per month is required from eligible participants, with no costs for Part D sponsors.
- Beneficiaries previously covered under standard Part D for GLP-1s are ineligible to participate in this program.
In a bid to tackle the obesity epidemic, CMS has rolled out the Medicare GLP-1 Bridge—a fancy name for a temporary program that lets certain Medicare beneficiaries access specific GLP-1 medications. Yes, you heard that right. It’s temporary, which means you can’t get too comfy. This program is just a short-term demonstration under Section 402 authority. Coverage will kick in on July 1, 2026, and wrap up by December 31, 2027. Apparently, they decided to extend it a bit—because who doesn’t love a last-minute change?
In a quirky twist, the Medicare GLP-1 Bridge offers temporary access to select obesity medications from July 2026 to December 2027.
So, what’s on the menu? CMS has chosen a narrow selection of covered products, including Foundayo, Wegovy, and the KwikPen formulation of Zepbound.
But hold your horses! Not all GLP-1s are included here; it’s strictly for obesity-related uses and specific formulations. You can’t just waltz in and expect to get any GLP-1 for weight loss. Access hinges on whether the drug is prescribed for a use that fits within this narrow framework. If you’re thinking you can swipe this for something else—think again.
Eligibility? Well, it’s limited to Medicare Part D beneficiaries. Additionally, this program operates outside Medicare Part D coverage and payment flow, meaning Part D sponsors won’t bear any financial responsibility. As of January 2026, only 13 states cover GLP-1s for obesity under Medicaid, highlighting the ongoing coverage gaps.
If you’re already covered under standard Part D, sorry, this bridge isn’t for you. Got type 2 diabetes or another condition that’s already covered? Tough luck. Plus, if you’ve snagged a GLP-1 through Part D in CY 2026, you’re out of luck for the bridge. Eligibility is a maze, folks—good luck finding your way through that.
Now let’s talk qualifications. Prescribers must attest that the drug is meant for reducing excess body weight, and yes, lifestyle changes are mandatory. Ongoing lifestyle modifications? You bet. If your BMI is 35 or higher, you’re golden. If it’s 30 or higher with a few health issues—okay, we’re interested. But if your BMI is just 27 and you’ve had a bad day? Sorry, that’s not enough.
Want to access this bridge? You’ll need a prior authorization request from your medical provider. They’ll need to confirm that you meet all those clinical criteria.
And let’s not forget about the cost—CMS lists a copay of $50 per month for those lucky enough to qualify. It’s not exactly pocket change, but it’s something. Notably, 40% of small businesses are statistically likely to face an insurance claim within 10 years, a reminder that unexpected costs can hit any budget when you least expect it. So there you have it: a complex, temporary solution to an ongoing problem, wrapped in red tape and a sprinkle of sarcasm. Good luck, everyone!
